These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 31102882)

  • 1. Adverse childhood experiences predict opioid relapse during treatment among rural adults.
    Derefinko KJ; Salgado García FI; Talley KM; Bursac Z; Johnson KC; Murphy JG; McDevitt-Murphy ME; Andrasik F; Sumrok DD
    Addict Behav; 2019 Sep; 96():171-174. PubMed ID: 31102882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Memantine improves buprenorphine/naloxone treatment for opioid dependent young adults.
    Gonzalez G; DiGirolamo G; Romero-Gonzalez M; Smelson D; Ziedonis D; Kolodziej M
    Drug Alcohol Depend; 2015 Nov; 156():243-253. PubMed ID: 26454835
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Parallel modeling of pain and depression in prediction of relapse during buprenorphine and naloxone treatment: A finite mixture model.
    Vest NA; McPherson S; Burns GL; Tragesser S
    Drug Alcohol Depend; 2020 Apr; 209():107940. PubMed ID: 32135429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
    Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
    Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medication-Assisted Treatment of Opioid Use Disorder in Adolescents and Young Adults.
    Cottrill CB; Matson SC
    Adolesc Med State Art Rev; 2014 Aug; 25(2):251-65. PubMed ID: 27132312
    [No Abstract]   [Full Text] [Related]  

  • 6. Primary care management of opioid use disorders: Abstinence, methadone, or buprenorphine-naloxone?
    Srivastava A; Kahan M; Nader M
    Can Fam Physician; 2017 Mar; 63(3):200-205. PubMed ID: 28292795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medication-assisted treatment for opioid use disorder within a 12-step based treatment center: Feasibility and initial results.
    Klein AA; Seppala MD
    J Subst Abuse Treat; 2019 Sep; 104():51-63. PubMed ID: 31370985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Buprenorphine/naloxone induction in a Canadian emergency department with rapid access to community-based addictions providers.
    Hu T; Snider-Adler M; Nijmeh L; Pyle A
    CJEM; 2019 Jul; 21(4):492-498. PubMed ID: 31006398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Investigation of Simulated Adherence in Long-Term Buprenorphine/Naloxone Treatment Patients.
    Rahman N; Janardhanan A; Shikalgar S; Pirkhan MA; Canner J; Skipwith C; Noor-E-Alam M
    Subst Use Misuse; 2024; 59(9):1275-1279. PubMed ID: 37950394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neuropsychological function is improved among opioid dependent adults who adhere to opiate agonist treatment with buprenorphine-naloxone: a preliminary study.
    Scott TM; Rivera Mindt M; Cunningham CO; Arias F; Coulehan K; Mangalonzo A; Olsen P; Arnsten JH
    Subst Abuse Treat Prev Policy; 2017 Nov; 12(1):48. PubMed ID: 29141650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine-naloxone treatment responses differ between young adults with heroin and prescription opioid use disorders.
    Romero-Gonzalez M; Shahanaghi A; DiGirolamo GJ; Gonzalez G
    Am J Addict; 2017 Dec; 26(8):838-844. PubMed ID: 29143399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical treatments for opioid use disorder in Iran: a randomized, double-blind placebo-controlled comparison of buprenorphine/naloxone and naltrexone maintenance treatment.
    Mokri A; Chawarski MC; Taherinakhost H; Schottenfeld RS
    Addiction; 2016 May; 111(5):874-82. PubMed ID: 26639678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors associated with non-adherence to Buprenorphine-naloxone among opioid dependent African-Americans: A retrospective chart review.
    Kumari S; Manalai P; Leong S; Wooditch A; Malik M; Lawson WB
    Am J Addict; 2016 Mar; 25(2):110-7. PubMed ID: 26749158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fulfilling a Need: A Residency-Based Program to Preserve a Suboxone Treatment Program in a Rural Community.
    Buck MC; McCormick AN; Meagher MM; Kauppila G; Witt TJ
    Ann Fam Med; 2021; 19(6):561. PubMed ID: 34750133
    [No Abstract]   [Full Text] [Related]  

  • 15. A preliminary randomized controlled trial of a distress tolerance treatment for opioid dependent persons initiating buprenorphine.
    Stein MD; Herman DS; Moitra E; Hecht J; Lopez R; Anderson BJ; Brown RA
    Drug Alcohol Depend; 2015 Feb; 147():243-50. PubMed ID: 25510307
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic.
    Matson SC; Hobson G; Abdel-Rasoul M; Bonny AE
    J Addict Med; 2014; 8(3):176-82. PubMed ID: 24695018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel Buccal Film Formulation of Buprenorphine-Naloxone for the Maintenance Treatment of Opioid Dependence: A 12-Week Conversion Study.
    Sullivan JG; Webster L
    Clin Ther; 2015 May; 37(5):1064-75. PubMed ID: 25823919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Volatility and change in chronic pain severity predict outcomes of treatment for prescription opioid addiction.
    Worley MJ; Heinzerling KG; Shoptaw S; Ling W
    Addiction; 2017 Jul; 112(7):1202-1209. PubMed ID: 28164407
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The problem of pain: Additive analgesic effect of tramadol and buprenorphine in a patient with opioid use disorder.
    Montalvo C; Genovese N; Renner J
    Subst Abus; 2019; 40(2):136-139. PubMed ID: 30835647
    [No Abstract]   [Full Text] [Related]  

  • 20. Are the Patients Ready for the Change?: An Empirical Study to Evaluate the Impact of Change in Formulation of Buprenorphine-Naloxone on Prescription Pattern, Treatment Adherence, and Patient Satisfaction.
    Balhara YPS; Singh S; Sarkar S
    Subst Use Misuse; 2019; 54(2):307-314. PubMed ID: 30513249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.